The classical approach to targeted drug delivery relies on the proximity of delivery to the active site such as in the use of 4 To whom correspondence should be addressed progesterone that are highly metabolized when taken orally The objective was to verify the hypothesis of a 'first and have such poor skin permeability that transdermal adminisuterine pass effect' or direct preferential vagina-to-uterus tration is impractical. During the course of previous experitransport, suggested by the evidence of higher than expected ments with vaginal progesterone it has become increasingly uterine tissue concentrations after vaginal administration apparent that uterine effects exceed the response that can of progesterone; we used a human ex-vivo uterine perfusion reasonably be expected from the circulating levels of progestermodel. A mixture of tritiated ( 3 H) and unlabelled progesterone achieved (De Ziegler et al., 1992; Miles et al., 1994). one was applied to the cuff of vaginal tissue remaining Similar findings have been reported with substances other than attached to the cervix after hysterectomy. At the end of progesterone, namely terbutaline (Kullander and Svanberg, the perfusion period (up to 12 h), 3 H and 14 C radioactivity 1985) and danazol (Mizutani et al., 1995) . These unexpected was measured in samples of uterine tissue. Tritiated water but markedly similar findings led us to postulate the existence and [ 14 C]dextran were tested to determine the extent of a preferential delivery to the uterus or a first uterine pass of non-specific vagina-to-uterus transport (leaks). Finally, effect of drugs administered vaginally.
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sections of uterine tissue exposed only to [ 3 H]progesterone
To challenge this provocative concept we used a human exwere prepared for autoradiography. By 4-5 h after applicavivo uterine perfusion model (Bulletti et al., 1986 (Bulletti et al., , 1987 , tion progesterone had diffused to the entire uterus and had 1988a,b). In these experiments we used freshly excised human reached a steady state; 4 h after application, progesterone uteri and applied [ 3 H]progesterone directly over the rim of concentrations reached 185 ⍨ 155 and 254 ⍨ 305 ng/100 vaginal tissue removed with the cervix and uterus at the time mg of endometrial and myometrial tissue respectively. of surgery. This method was chosen rather than animal studies Endometrial extraction of progesterone was higher when because of the species-specific differences in the utero-vaginal the experiment was performed on uteri obtained during tract and the advantages of an open circulatory system that the luteal phase (280 ⍨ 156 ng/100 mg of endometrial allowed us to exclude contaminations inherently linked to the tissue) than those removed during the proliferative phase recirculation of radioactive compounds. of the menstrual cycle (74 ⍨ 28 ng/100 mg of endometrial tissue). These data demonstrate that a 'first uterine pass Materials and methods effect' occurs when drugs are delivered vaginally, thereby providing an explanation for the unexpectedly high uterine Introduction menstrual cycles. The histological examination was used to confirm In recent years targeted drug delivery has become one of the the phase of menstrual cycle. Five experiments were performed to prime objectives in the development of new dosage forms.
establish the non-specific uptake by uterine tissues of membraneTargeted delivery is designed to maximize the therapeutic impermeable dextran at different intervals (1, 2, 3, 4, 12 h) . Nine experiments were used to determine the accumulation of progesterone effect while minimizing the potential for systemic side-effects.
in the endometrium and myometrium 1 (n ϭ 3), 2 (n ϭ 3) and 3 (vagina or myometrium)/( 14 C/ 3 H) mixture here used for the vaginal administration. O the time required to observe complete uterine impregnation after vaginal administration of progesterone. Nine other uteri were used to was applied to the vaginal cuff to determine both the extraction of progesterone from uterine tissues and transit time of this mixture establish the amount of progesterone remaining in the uterine tissue or washed out through the uterine veins at 5 (n ϭ 3), 6 (n ϭ 3) and through the organ when a constant flow rate of 25 ml/min was maintained in the arterial perfusion. Because of its membrane imper-12 (n ϭ 3) h after its vaginal application, respectively. Finally, four uteri used for autoradiography studies were exposed to a single tracer, meability, [ 14 C]dextran radioactivity was used as a reflector of nonspecific transport from the vaginal collar to the uterine tissues. The [ 3 H]progesterone. These four uteri were not available for histological and pharmacokinetic studies.
oil solution applied on the vagina contained~26 µCi [ 3 H]progesterone and 1.5 µCi of [ 14 C]butanol. Uterine extraction of isotopes applied Perfusion procedure vaginally was taken as evidence of direct vagina-to-uterus transport or 'first uterine pass effect' of these substances. Because the experimental Uterine perfusions were performed using a technique extensively uterine perfusion model avoided re-circulation of the perfusate, reported (Bulletti et al., 1986 (Bulletti et al., , 1987 (Bulletti et al., , 1988a increased from the first to third hour and remained constant thereafter Transport to the uterus (calculated as whole organ, vaginal, endometfor up to 6 h of uterine perfusion. Hence, uterine extraction data of rial or myometrial extraction) was measured 1, 2, 3, 4, 5, 6 and 12 h vaginally administered test or reference substances were calculated after the vaginal application of the oil containing the mixture of either from specimens analysed ജ4 h after the application of the radioactive radioactive (hot) and non-radioactive (cold) test (progesterone) or test of mixture. According to Pardridge (1981) and butanol respectively, 4 h after vaginal application of the oil, and autoradiography. Experiments were interrupted at predetermined time TII the tissue influx index. Statistical analysis of the results was intervals after vaginal application of the mixture of hot and cold performed by the Student's two-tailed t-test with two independent progesterone and samples of vagina, myometrium and endometrium means for each individual experiment. were taken with a through-cut biopsy needle (Travenol Laboratories, Deerfield, IL, USA) or a Novak (Chirurgica, Bologna, Italy) curette Autoradiography respectively. These samples were used for histology and determination Autoradiography was performed from thin transverse sections (~5 of 3 H and 14 C levels. Representative tissue samples of vagina, mm) of the perfused uteri obtained after 1, 2, 3 and 4 h after vaginal endometrium or myometrium (~100 mg) were obtained from each application of the standard dose of [ 3 H]progesterone. Uterine sections uterus and dissolved in 1 ml of Soluene (Packard Instruments, of the organ featuring the endometrial tissue in its centre were Chicago, IL, USA) and 15 ml of scintillation fluid (Dimilume 30, obtained at different distances from the internal os of the cervix in Packard Instruments). Moreover, aliquots of the original oil solutions order that the autoradiography data could be used to assess the used to administer the mixture of cold and hot progesterone and of time dependency of the uterine invasion by vaginally administered venous effluent were similarly prepared for double-isotope liquid progesterone. Tissue sections were positioned on Hyperfilm 3 H 18ϫ24 scintillation counting in an LKB 1215 Rackbeta 2 scintillation cm (code RPN 535) obtained from Amersham Italia s.r.l. (Milan, spectrometer (LKB-Produkter AB, Bromma, Sweden). A ratio of at Italy) for 28 days at -80°C. least 2:1 of 3 H-labelled test to 14 C-labelled reference radioactivity was used to minimize the error of 14 C radioactivity overlapping into the 3 H channel. Isotope counts per min were converted to progesterone extracted by these tissues, a value that needed to Pardridge (1981) , Pardridge and Mietus (1979) , Laufer et al. (1983), be subtracted from the amounts of [ 3 H]progesterone counted Verheugen et al. (1984) and Steingold et al. (1986) . In this paradigm, the index for dextran was calculated as ( 14 C/ 3 H) in endometrium in tissue samples. Figure 1 shows the endometrial extraction as established from all the reported experiments (extraction data and autoradiography).
The mean Ϯ SD extractions of progesterone from specimens of progesterone and the corresponding venous outflow of this obtained 4 h after vaginal application during the proliferative compound during the 12 h uterine perfusions that followed phase were 74 Ϯ 28 ng (n ϭ 5) and 141 Ϯ 161 ng (n ϭ vaginal application of labelled and unlabelled progesterone on 5)/100 mg of endometrium and myometrium respectively, 30 organs. The [ 3 H]progesterone started to be recovered in compared with 280 Ϯ 156 ng (n ϭ 7) (P Ͻ 0.01) and uterine effluent during the first hour of perfusion (33 Ϯ 9% of 346 Ϯ 367 ng (n ϭ 7) (not significantly different)/100 mg of total dose, mean Ϯ SD) and persisted to efflux from the uterus endometrium and myometrium respectively in organs obtained during the second hour (31 Ϯ 12% of total dose). Thereafter, during the secretory phase of the menstrual cycle (Figure 4a,b) . progesterone outflow decreased during the third and fourth hours of perfusion (10 Ϯ 5% and 10 Ϯ 11% respectively) and Discussion remained constant at 5 Ϯ 3%, 5 Ϯ 2% and 4 Ϯ 4% during the fifth, sixth and 12th hours of perfusion respectively. The
The study demonstrated that in this human ex-vivo uterine perfusion model radioactive progesterone applied to the vaginal mean Ϯ SD extractions of progesterone from 100 mg of endometrium collected at timed intervals after vaginal applicacuff, remaining after hysterectomy, progressively migrates into the uterus and reaches high concentration in both the tion of the [ 3 H]-and cold progesterone loads were: 12 Ϯ 10 ng (n ϭ 3), 99 Ϯ 19 ng (n ϭ 3), 132 Ϯ 37 ng (n ϭ 3), endometrium and the myometrium. Hence, vaginal drug administration results in high uterine concentration (Miles et al., 188 Ϯ 155 ng (n ϭ 12), 265 Ϯ 64 ng (n ϭ 3), 212 Ϯ 46 ng (n ϭ 3) and 95Ϯ34 ng (n ϭ 3) after 1, 2, 3, 4, 5, 6 and 12 h 1994; Mizutani et al., 1995) associated with a direct transport from the vagina to the uterus -the first uterine pass effect. respectively. The mean Ϯ SD extractions of progesterone from 100 mg of myometrium (data not shown) collected at the same In an elegant study conducted on agonadal women preparing for embryo donation Miles et al. (1994) observed that vaginal timed intervals after vaginal application of progesterone were: 0 ng (n ϭ 3), 31 Ϯ 5 ng (n ϭ 3), 267 Ϯ 84 ng (n ϭ 3), administration of micronized progesterone enhanced progesterone delivery to the uterus by~10-fold when compared to 254 Ϯ 305 ng (n ϭ 12), 299 Ϯ 87 ng (n ϭ 3), 223 Ϯ 98 ng (n ϭ 3), 77 Ϯ 23 ng (n ϭ 3). The endometrial and myometrial i.m. injections despite the markedly higher (~7-fold greater) circulating concentrations achieved with i.m. administration. extractions of progesterone 4 h after vaginal application on 12 uteri are reported in Figure 2 . For comparison simultaneous Remarkably, in this and other studies, vaginal progesterone reliably induced a synchronous secretory transformation of extraction from vaginal tissue was also reported (6.5 ϩ 9.7 µg/100 mg of tissue) and depicted in Figure 2 . the endometrium (Miles et al., 1994) . A similar uterotrophic paradox was found when serum and uterine concentrations of After 4 h of perfusion of four organs, autoradiography of uterine sections showed uniform capture of radioactivity by danazol were compared following either vaginal delivery of 100 mg/day or oral administration of 400 mg/day (Mizutani the endometrium in all the sections obtained as illustrated in Figure 3 (top left and right). In the myometrium, however, et al., 1995) . Consistent with this theory of uterine selectivity after vaginal administration is the observation of Kullander autoradiography showed an apparent accumulation of radioactive tracer in, or near, vascular casts. Figure 3 (bottom left and and Svanberg (1985) that vaginal administration of the β-agonist terbutaline in women just prior to hysterectomy right) shows the progression of the front of progesterone and Progesterone accumulated in the endometrium (in the middle of the radiographs), around the organ, in the external third of the muscle, and, apparently, around the vessels. The endometrial uptake of radioactive progesterone (in the centre) was obtained by cutting transverse sections of the organ at different distances from the internal os of the cervix, in order to collect autoradiography data enabling an assessment of time dependency of the uterine invasion by vaginally administered progesterone. The front of migration of progesterone is reported in the diagrams in (bottom left) and (bottom right) as a function of time after its application during the extracorporeal perfusion of the uterus (n ϭ 4). Radioactive test substances were resulted in uterine vein drug concentrations that exceeded 3 H recovered from the venous effluent was a reflection of progesterone exiting from the organ. Chromatographic analysis those in the general circulation. The practical applications of direct vagina-to-uterus transport have already been utilized in of the perfusate should determine whether local progesterone metabolism occurred in the uterus and this will be the subject clinical trials. Hausknecht (1995) showed that the vaginal administration of misoprostol tablets after the parenteral adminof an additional study. The quantity of [ 14 C]dextran that accumulated in the uterine tissue 4 h after vaginal application istration of methotrexate induced a reliable termination of early pregnancies, thereby confirming the greater efficiency of represents an aspecific vagina-to-uterus transport because dextran is a membrane-impermeable compound. vaginal versus oral misoprostol in inducing uterine contractions (El-Refaey et al., 1995) .
The accumulation of radioactive tracer observed by autoradiography appears homogeneous in the endometrial tissue The prompt migration of progesterone into the uterine tissue in a human in-vitro extracorporeal perfusion non-recycling but myometrial uptake shows a less uniform dispersion. There is a notable accumulation of [ 3 H]progesterone around vascular system provides the documentary evidence of direct vaginato-uterus transport. Since progesterone administered vaginally casts ( Figure 3 top left and right). This observation may be seen as supporting the hypothesis of a counter arterial-toaccumulates in the uterus disproportionately compared with the situation after oral ingestion, a vagina-to-uterus diffusion venous perfusion. Alternatively, passive diffusion possibly facilitated by rhythmic peristaltic-like uterine contractions system permitting the concentration of hormone independent of its vascular effluent levels can be postulated. The phenomenon may be followed by vessel capture of steroids leading to radioactivity accumulation in the film. Yet despite autoradiodemonstrated by our experiment with the in-vitro uterine perfusions shows that a fraction of the vaginally administered graphy showing a lower accumulation of radioactive progesterone in the myometrium, higher tissue concentrations progesterone reaches the uterus before being transported elsewhere in the body which is equivalent to a functional analogue were found in the myometrium than in the endometrium. It is possible that radioactive progesterone accumulates in the of an anatomical portal system. The current study is an adaptation of a model originally walls of vessels, thereby mapping their topography on the autoradiographic film, whereas radioactivity in the extravascudeveloped to delineate the transport of steroids from the vascular compartment to the uterine tissue (Bulletti et al., lar system, which is more diffused in the myometrium than endometrium, is not detected on the film. Since the ratio of 1988a) in order to assess the response to steroid hormones ex vivo (Bulletti et al., 1987) and the electromechanical events vessels to extravascular tissue is higher in the endometrium than the myometrium, this could explain why there is a induced (Bulletti et al., 1993) . Moreover, the physiological nature of this ex-vivo model was demonstrated in a previous more homogeneous appearance of the endometrium with autoradiography. study which showed that the early steps of embryo implantation occur when the uterus is maintained in this perfusion system Moreover, the cyclical development of a complex network of microvessels in the endometrium that culminates during the (Bulletti et al., 1988b) .
After 4 h of uterine perfusion, a steady state level in tissue luteal phase of the menstrual cycle may explain the differences in progesterone concentrations observed between phases of was achieved. Tissue concentrations after vaginal administration of [ 3 H]progesterone and the radioactivity recovered from the cycle in which the uteri were obtained. Two other mechanisms could also help explain the higher accumulation of the venous effluent also reached steady state. The quantity of progesterone in the endometrium during the luteal phase. First, glucose metabolism which limit oral and parenteral use of these agents. a higher concentration of progesterone receptors might account for higher accumulation during the early luteal phase; however, Another group of potentially useful utero-relaxants, the nitric oxide donors such as nitroglycerine, may also benefit progesterone receptors are already present in the late follicular phase and disappear from the endometrial gland during the from targeted delivery to the uterus. The clinical advantage of administering utero-contractant drugs such as misoprostol second half of the luteal phase. Second, the different patterns of uterine contractility that have been observed in the two vaginally has already been demonstrated (Hausknecht, 1995) . An added advantage of the vaginal route of administration is phases of the menstrual cycle (Bulletti et al., 1993) could also provide an explanation for the different degrees of radioactive the potential to sustain the release by admixing the drug with a bioadhesive gel (De Ziegler et al., 1995) thereby combining capture, possibly by an enhanced facilitation of passive transportation at given times in the menstrual cycle.
the advantages of non-oral targeted administration with those of controlled and sustained release. Finally, our demonstration Targeting drug delivery through vaginal administration is particularly appealing for substances destined to exert their of a first uterine pass effect offers a fascinating new perspective for the development of vaginal contragestive therapy, which primary action on the uterus itself. This includes progesterone that is needed to antagonize the proliferative effects of oestrocan alter endometrial receptivity without changing the cyclical production of sex hormones. gen replacement therapy on the endometrium, to prepare the endometrium for embryo implantation in assisted reproductive techniques and for luteal phase support in infertility treatments
